Icotinib plus chemo before surgery for EGFR-mutated lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests adding icotinib (an EGFR-targeted pill) to chemotherapy before surgery for people with certain EGFR-mutated lung adenocarcinoma. The goal is to shrink or better control the cancer before it’s removed with an operation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and 75 years old and can sign informed consent
- You have lung adenocarcinoma that can be fully removed by surgery (resectable disease)
- Your tumor has an EGFR mutation called Ex19del or L858R (not just any EGFR change)
- You must not have had prior anti-cancer medicine for lung cancer, EGFR pills, or pre-op radiation
- Your health status should be good (ECOG 0–1) and should not have worsened in the last 2 weeks
- Blood tests and organ function must meet minimum thresholds (including enough blood counts and kidney/liver function)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, immunotherapy (QL1706), and chemotherapy given before surgery for non-small-cell lung cancer that can be removed. It aims to see if this approach can shrink the tumor and improve outcomes.
This trial studies how well a targeted medicine (icotinib) combined with chemotherapy works before surgery for certain EGFR-mutated lung adenocarcinoma. The goal is to shrink or control the tumor and make surgery more effective.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (sintilimab) before surgery helps people with a specific type of lung cancer (EGFR-mutant, non-small cell) that is at a stage where surgery can be considered. The goal is to improve outcomes by shrinking the tumor before the operation.
This trial tests if a targeted therapy pill (befotertinib) can lower the chance of cancer coming back after surgery for non-small cell lung cancer that has a specific EGFR mutation. You may be eligible if your tumor was completely removed and you have stage IB to IIIB disease.
This study tests whether giving osimertinib together with chemotherapy before surgery can shrink and control EGFR-mutant, stage III lung cancer so it can be fully removed. If it works, it may improve the chances that the cancer does not come back after surgery.
This trial tests different treatments after surgery for people with non-squamous lung cancer that has certain high-risk features. The goal is to find the best next step to lower the chance of the cancer coming back, based on the type of gene change in the tumor.
Hear when a new EGF-R Positive Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.